Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BY 4.0Oncology Research

Advances in Novel Protein Acylation in Urothelial Carcinoma: Research Progress and Biomarker Potential

  • Xiyue Dong1,2
  • Jiankun Zhang1,2
  • Meixi Liu3
  • Ruiqiang Sun1,2
  • Yuanshan Cui2
  1. 1School of Clinical Medicine, Shandong Second Medical University, Weifang, China
  2. 2Department of Urology, Weifang People’s Hospital, Weifang, China
  3. 3Weifang No. 1 Middle School, Weifang, China
Read full textPDFDOICite

Abstract

Protein acylation serves as an important molecular bridge between metabolic status and cellular function. It is becoming a key entry point for understanding tumor initiation, progression, and treatment resistance. In urothelial carcinoma (UC), metabolic reprogramming may alter the availability of acyl donors, including lactyl-CoA (coenzyme A), succinyl-CoA, crotonyl-CoA, and palmitoyl-CoA. This can affect acylation on both histone and non-histone proteins. This review focuses on four metabolism-related acylation modifications: lactylation, succinylation, crotonylation, and palmitoylation. Itummarizes their regulatory mechanisms, biological functions, and recent research progress in cancer. It further discusses their potential roles in UC progression, immune remodeling, inflammation regulation, treatment resistance, and biomarker development. Current evidence suggests that metabolism-dependent acylation modifications may promote malignant progression of UC by coordinating tumor metabolism, epigenetic regulation, and oncogenic signaling pathways. Therefore, this review aims to summarize recent advances in novel protein acylation modifications in UC, clarify their dynamic regulatory networks, and discuss their potential value in disease classification, prognostic assessment, therapeutic target identification, and personalized treatment strategies.

Related

  1. Myeloid-Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13–CXCL8 Transcriptomic Biomarker Across Renal Cell and Urothelial Carcinoma
    Mario Uccello
    Current issues in molecular biologyPeer-reviewedCC BYFull textOncologyEurope PMCDOAJ
  2. Transcriptomic Profiling Reveals METTL26 as a Potential Biomarker in Head and Neck Squamous Cell Carcinoma with Independent Validation in Oral Squamous Cell Carcinoma
    Rossella Rotondo, Alessandro Polizzi, Sabrina Donati Zeppa +3
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Pan-cancer analysis identifies ANGPT4 as a potential prognostic biomarker associated with the tumor microenvironment in kidney renal clear cell carcinoma
    Pengfei Chen, Kangmei Tong, Lisheng You +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  4. Exploring the biomarker potential of LCN2 and MMP9 proteins in Head and Neck Squamous Cell Carcinoma
    Smriti Suri, Monil Parsana, Himanshu Garg +8
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  5. MUC5AC Protein Expression as a Potential Predictor of Metastasis in Mucinous Ovarian Carcinoma: Unveiling a New Biomarker in a Rare Cancer Subtype
    Rina Masadah, Syahrul Rauf, Desy Ekadamadayani Ahmad +1
    Asian Pacific Journal of Cancer Prevention : APJCPPeer-reviewedCC BY-NC 4.0Full textOncologyPMC

Cite

BibTeXRIS
BibTeX
@article{dong2026advances,
  title = {{Advances in Novel Protein Acylation in Urothelial Carcinoma: Research Progress and Biomarker Potential}},
  author = {Xiyue Dong and Jiankun Zhang and Meixi Liu and Ruiqiang Sun and Yuanshan Cui},
  journal = {Oncology Research},
  year = {2026},
  month = oct,
  doi = {10.32604/or.2026.084336},
  url = {https://doi.org/10.32604/or.2026.084336},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Advances in Novel Protein Acylation in Urothelial Carcinoma: Research Progress and Biomarker Potential
AU  - Xiyue Dong
AU  - Jiankun Zhang
AU  - Meixi Liu
AU  - Ruiqiang Sun
AU  - Yuanshan Cui
PY  - 2026
DA  - 2026/10/28
JO  - Oncology Research
DO  - 10.32604/or.2026.084336
UR  - https://doi.org/10.32604/or.2026.084336
AB  - Protein acylation serves as an important molecular bridge between metabolic status and cellular function. It is becoming a key entry point for understanding tumor initiation, progression, and treatment resistance. In urothelial carcinoma (UC), metabolic reprogramming may alter the availability of acyl donors, including lactyl-CoA (coenzyme A), succinyl-CoA, crotonyl-CoA, and palmitoyl-CoA. This can affect acylation on both histone and non-histone proteins. This review focuses on four metabolism-related acylation modifications: lactylation, succinylation, crotonylation, and palmitoylation. Itummarizes their regulatory mechanisms, biological functions, and recent research progress in cancer. It further discusses their potential roles in UC progression, immune remodeling, inflammation regulation, treatment resistance, and biomarker development. Current evidence suggests that metabolism-dependent acylation modifications may promote malignant progression of UC by coordinating tumor metabolism, epigenetic regulation, and oncogenic signaling pathways. Therefore, this review aims to summarize recent advances in novel protein acylation modifications in UC, clarify their dynamic regulatory networks, and discuss their potential value in disease classification, prognostic assessment, therapeutic target identification, and personalized treatment strategies.
SN  - 0965-0407
SN  - 1555-3906
ER  -